Halozyme Therapeutics Inc.’s stock price has surged to a price of $38.8 today. With their 10.0% increase, HALO shares outpaced both the S&P 500 and Dow Industrial composite indices by 0.0%, but are still well below their 52 week high of $59.46. Over the last 12 months, Halozyme Therapeutics is down 15.0%, and has underperformed the S&P 500 by 30.0%. Now, the mid-cap Health Care company is 25.24% below its average target price of $51.9 and has an average analyst rating of buy.
Halozyme Therapeutics's trailing 12 month price to earnings (P/E) ratio is 20.7, which is its share price divided by its trailing earnings per share (EPS) of $1.87. The company has a forward P/E ratio of 10.5 based on its forward EPS of $3.7 -- which is an estimate of future earnings provided by management. The P/E ratio tells us how much investors are willing to pay for each dollar of the company's net earnings from its sales operations. By way of comparison, the average P/E ratio of the Health Care sector is 24.45, but a company's price can remain stable for a long time even if it is over or undervalued.
Company accountants calculate earnings by subtracting the costs of sales and overhead from its revenues. These metrics focus on the sales side of the company only -- it's important to remember that companies can have many other costs and sources of income that are independent from its core business. For example, a company may have extensive expenses such as rent and debt servicing, and on the other hand it may receive additional income from its investments and intellectual property.
So the earnings picture only shows a slice of the company's financial health. They also don’t represent actual inflows of cash, since revenues are calculated on the basis of product or service deliveries, as opposed to actual payments received. The importance of earnings is that they enable us to analyze the company’s growth and profitability over time.
Here is an overview of Halozyme Therapeutics’s operating margins, which are the percentage of net profit compared to total revenues:
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 773,653 | 467,592 | 40 | -2.44 |
| 2022 | 660,116 | 392,585 | 41 | -33.87 |
| 2021 | 443,310 | 167,408 | 62 | 14.81 |
| 2020 | 267,594 | 123,339 | 54 | 258.82 |
| 2019 | 195,992 | 263,602 | -34 | 26.09 |
| 2018 | 151,862 | 221,192 | -46 |
- Average operating margins: 19.5 %
- Average operating margins growth rate: 10.9 %
- Coefficient of variability (the lower the better): 602.2 %
Let’s contrast the operating margins with an overview of Halozyme Therapeutics’s gross margins, which only take into account expenses directly related to producing revenue (i.e. without overhead):
| Date Reported | Revenue ($ k) | Cost of Revenue ($ k) | Gross Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 773,653 | 467,592 | 40 | -2.44 |
| 2022 | 660,116 | 392,585 | 41 | -33.87 |
| 2021 | 443,310 | 167,408 | 62 | 14.81 |
| 2020 | 267,594 | 123,339 | 54 | 258.82 |
| 2019 | 195,992 | 263,602 | -34 | 26.09 |
| 2018 | 151,862 | 221,192 | -46 |
- Average gross margins: 19.5 %
- Average gross margins growth rate: 10.9 %
- Coefficient of variability (the lower the better): 602.2 %
Another metric for valuing a stock is its Price to Book (P/B) Ratio, which consists in its share price divided by its book value per share. The book value refers to the present value of the company if it were liquidated today (i.e. selling all assets and paying off all debts). Halozyme Therapeutics's P/B ratio indicates that the market value of the company exceeds its book value by a factor of 21.0, so the company's assets may be overvalued compared to the average P/B ratio of the Health Care sector, which stands at 4.16.
HALO's average free cash flow over the last few years is $122.57 Million, which represents the sum of inflows and outflows of cash from all sources, including capital expenses.. This is the pool of liquidity that the company can use to reinvest in its business or pay out to its equity investors in the form of a dividend. Despite having cash on hand for this purpose, Halozyme therapeutics has not offered a dividend within the last twelve months.
Since it has a an average P/E ratio, an elevated P/B ratio, irregular cash flows, and decent operating margins, Halozyme Therapeutics is probably overvalued at current prices. Make sure to complement this brief quantitative review with a qualitative analysis of your own!
